Literature DB >> 32399855

Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.

Dimitrios Velissaris1, George Dimopoulos2, John Parissis3, Zoi Alexiou4, Nikolaos Antonakos5, Dimitrios Babalis6, Styliani Gerakari7, Vassileios Kaldis8, Pantelis Koutoukas9, Malvina Lada10, Konstantinos Leventogiannis5, Ioannis Pantazopoulos11, Antonios Papadopoulos5, Eftihia Polyzogopoulou3, Charalambos Gogos1, Apostolos Armaganidis2, Evangelos J Giamarellos-Bourboulis12.   

Abstract

In light of the accumulating evidence on the negative predictive value of soluble urokinase plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care medicine, emergency medicine, internal medicine and infectious diseases frame a position statement on the role of suPAR in the screening of patients admitted to the emergency department. The statement is framed taking into consideration existing publications and our own research experience. The main content of this statement is that sUPAR is a non-specific marker associated with a high negative predictive value for unfavourable outcomes; levels < 4 ng/ml indicate that it is safe to discharge the patient, whereas levels > 6 ng/ml are an alarming sign of risk for unfavourable outcomes. However, the suPAR levels should always be interpreted in light of the patient's history.

Entities:  

Keywords:  Emergency department; Mortality; Triage; suPAR

Year:  2020        PMID: 32399855      PMCID: PMC7217599          DOI: 10.1007/s40121-020-00301-w

Source DB:  PubMed          Journal:  Infect Dis Ther        ISSN: 2193-6382


  15 in total

1.  Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.

Authors:  Athina Savva; Maria Raftogiannis; Fotini Baziaka; Christina Routsi; Anastasia Antonopoulou; Pantelis Koutoukas; Thomas Tsaganos; Anastasia Kotanidou; Efterpi Apostolidou; Evangelos J Giamarellos-Bourboulis; George Dimopoulos
Journal:  J Infect       Date:  2011-08-03       Impact factor: 6.072

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 3.  Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis.

Authors:  K L Liu; J H Fan; Jing Wu
Journal:  Clin Lab       Date:  2017-05-01       Impact factor: 1.138

4.  Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.

Authors:  Athina Chounta; Christofer Ellinas; Vassiliki Tzanetakou; Fani Pliarhopoulou; Virginia Mplani; Angelos Oikonomou; Kostantinos Leventogiannis; Evangelos J Giamarellos-Bourboulis
Journal:  Liver Int       Date:  2014-11-20       Impact factor: 5.828

5.  Soluble Urokinase Receptor and Acute Kidney Injury.

Authors:  Salim S Hayek; David E Leaf; Ayman Samman Tahhan; Mohamad Raad; Shreyak Sharma; Sushrut S Waikar; Sanja Sever; Alex Camacho; Xuexiang Wang; Ranadheer R Dande; Nasrien E Ibrahim; Rebecca M Baron; Mehmet M Altintas; Changli Wei; David Sheikh-Hamad; Jenny S-C Pan; Michael W Holliday; James L Januzzi; Steven D Weisbord; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

Review 6.  Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.

Authors:  Charles Edo de Bock; Yao Wang
Journal:  Med Res Rev       Date:  2004-01       Impact factor: 12.944

7.  Soluble Urokinase Receptor and Chronic Kidney Disease.

Authors:  Salim S Hayek; Sanja Sever; Yi-An Ko; Howard Trachtman; Mosaab Awad; Shikha Wadhwani; Mehmet M Altintas; Changli Wei; Anna L Hotton; Audrey L French; Laurence S Sperling; Stamatios Lerakis; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

8.  Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.

Authors:  Evangelos J Giamarellos-Bourboulis; Anna Norrby-Teglund; Vassiliki Mylona; Athina Savva; Iraklis Tsangaris; Ioanna Dimopoulou; Maria Mouktaroudi; Maria Raftogiannis; Marianna Georgitsi; Anna Linnér; George Adamis; Anastasia Antonopoulou; Efterpi Apostolidou; Michael Chrisofos; Chrisostomos Katsenos; Ioannis Koutelidakis; Katerina Kotzampassi; George Koratzanis; Marina Koupetori; Ioannis Kritselis; Korina Lymberopoulou; Konstantinos Mandragos; Androniki Marioli; Jonas Sundén-Cullberg; Anna Mega; Athanassios Prekates; Christina Routsi; Charalambos Gogos; Carl-Johan Treutiger; Apostolos Armaganidis; George Dimopoulos
Journal:  Crit Care       Date:  2012-08-08       Impact factor: 9.097

9.  Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.

Authors:  Martin Schultz; Line J H Rasmussen; Thomas Høi-Hansen; Erik Kjøller; Birgitte N Jensen; Morten N Lind; Lisbet Ravn; Thomas Kallemose; Theis Lange; Lars Køber; Lars S Rasmussen; Jesper Eugen-Olsen; Kasper K Iversen
Journal:  Dis Markers       Date:  2019-05-19       Impact factor: 3.434

10.  Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.

Authors:  Wolfgang Winnicki; Gere Sunder-Plassmann; Gürkan Sengölge; Ammon Handisurya; Harald Herkner; Christoph Kornauth; Bernhard Bielesz; Ludwig Wagner; Željko Kikić; Sahra Pajenda; Thomas Reiter; Benjamin Schairer; Alice Schmidt
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

View more
  8 in total

1.  suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19.

Authors:  Izzet Altintas; Jesper Eugen-Olsen; Santeri Seppälä; Jens Tingleff; Marius Ahm Stauning; Nora Olsen El Caidi; Sanaá Elmajdoubi; Hejdi Gamst-Jensen; Mette B Lindstrøm; Line Jee Hartmann Rasmussen; Klaus Tjelle Kristiansen; Christian Rasmussen; Jan O Nehlin; Thomas Kallemose; Harri Hyppölä; Ove Andersen
Journal:  Biomark Insights       Date:  2021-08-15

2.  Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients.

Authors:  Ria M Holstein; Santeri Seppälä; Johanna Kaartinen; Mari Hongisto; Harri Hyppölä; Maaret Castrén
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

Review 3.  Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.

Authors:  Dimitrios Velissaris; Nicholas Zareifopoulos; Ioanna Koniari; Vasilios Karamouzos; Dimitris Bousis; Andreas Gerakaris; Christina Platanaki; Nicholas Kounis
Journal:  J Clin Med Res       Date:  2021-03-19

4.  suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department.

Authors:  Seppälä Santeri; Andersen Andreas Peter; Nyyssönen Kristiina; Eugen-Olsen Jesper; Hyppölä Harri
Journal:  BMC Emerg Med       Date:  2021-11-29

5.  Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study.

Authors:  Dimitrios Velissaris; Maria Lagadinou; Themistoklis Paraskevas; Eleousa Oikonomou; Vasileios Karamouzos; Sofia Karteri; Dimitrios Bousis; Nikolaos Pantzaris; Konstantinos Tsiotsios; Markos Marangos
Journal:  J Clin Med Res       Date:  2021-09-30

6.  Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19.

Authors:  Helena Enocsson; Cornelia Idoff; Annette Gustafsson; Melissa Govender; Francis Hopkins; Marie Larsson; Åsa Nilsdotter-Augustinsson; Johanna Sjöwall
Journal:  Front Med (Lausanne)       Date:  2021-12-02

7.  Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making.

Authors:  Ria M Holstein; Marja T Mäkinen; Maaret K Castrén; Johanna M Kaartinen
Journal:  Biomark Insights       Date:  2022-03-09

Review 8.  Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.

Authors:  Line Jee Hartmann Rasmussen; Jens Emil Vang Petersen; Jesper Eugen-Olsen
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.